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Abstract
Background
Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19.
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Methods
Studies evaluating remdesivir in adults with hospitalized COVID-19 were searched in several engines until August 21, 2020. Primary outcomes included all-cause mortality, clinical
improvement or recovery, need for invasive ventilation, and serious adverse events (SAEs).
Inverse variance random effects meta-analyses were performed.

Results
We included four randomized controlled trials (RCTs) (n = 2296) [two vs. placebo (n = 1299)
and two comparing 5-day vs. 10-day regimens (n = 997)], and two case series (n = 88).
Studies used intravenous remdesivir 200mg the first day and 100mg for four or nine more
days. One RCT (n = 236) was stopped early due to AEs; the other three RCTs reported outcomes between 11 and 15 days. Time to recovery was decreased by 4 days with remdesivir
vs. placebo in one RCT (n = 1063), and by 0.8 days with 5-days vs. 10-days of therapy in
another RCT (n = 397). Clinical improvement was better for 5-days regimen vs. standard of
care in one RCT (n = 600). Remdesivir did not decrease all-cause mortality (RR 0.71, 95%
CI 0.39 to 1.28, I2 = 43%) and need for invasive ventilation (RR 0.57, 95%CI 0.23 to 1.42, I2
= 60%) vs. placebo at 14 days but had fewer SAEs; 5-day decreased need for invasive ventilation and SAEs vs. 10-day in one RCT (n = 397). No differences in all-cause mortality or
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SAEs were seen among 5-day, 10-day and standard of care. There were some concerns of
bias to high risk of bias in RCTs. Heterogeneity between studies could be due to different
severities of disease, days of therapy before outcome determination, and how ordinal data
was analyzed.

Conclusions
There is paucity of adequately powered and fully reported RCTs evaluating effects of
remdesivir in hospitalized COVID-19 patients. Until stronger evidence emerges, we cannot
conclude that remdesivir is efficacious for treating COVID-19.

Introduction
Worldwide, ~50 million patients have been infected with Coronavirus Disease 2019 (COVID19), resulting in over 1.2 million deaths [1]. Older populations with obesity, hypertension, diabetes, and chronic kidney disease have a poorer prognosis when infected [2]. In the most
severely ill COVID-19 patients, corticosteroid therapy has been shown to prolong survival but
no other drugs have demonstrated efficacy in randomized controlled trials (RCTs) with a reasonable safety profile [3–5].
Remdesivir inhibits ribonucleic acid (RNA) polymerase limiting viral replication [6, 7]. It
was originally developed to treat Ebola but promising in vitro effects were not translated into
acceptable clinical efficacy. Remdesivir provides antiviral effects on coronaviruses in vitro and
early initiation of therapy significantly reduced pulmonary damage in monkeys infected with
COVID-19 [6, 8]. Remdesivir received Food and Drug Administration (FDA) Emergency Use
Authorization (EUA) on May 1st 2020 and was approved on October 22, 2020 [9]. We systematically evaluated the human studies assessing the efficacy and safety of remdesivir for the
treatment of COVID-19.

Materials and methods
Search strategy and selection criteria
We performed a systematic review of RCTs and observational studies evaluating the effects of
remdesivir in adult hospitalized COVID-19 patients with pneumonia and/or respiratory insufficiency. We searched for studies in PubMed, Web of Science, Scopus, Embase and the
Cochrane Library, and medRxiv.org and for ongoing RCTs in www.ClinicalTrials.gov, www.
who.int/ictrp/about/en/, and www.clinicaltrialsregister.eu/. Databases were searched on May
5th, 2020 and updated on June 5th, 2020 and August 21, 2020.
Search strategies were adjusted for each engine using the keywords: remdesivir AND
(COVID-19 OR coronavirus OR coronavirus disease OR coronavirus disease-19 OR severe
acute respiratory syndrome OR SARS-CoV-2) with no limitations for time or language. The
PubMed strategy is included in the S1 File. Included studies in our search involved case series,
cohorts and RCTs that specified at least one efficacy or harm outcome. We excluded studies
with hepatitis B or HIV coinfection patients.

Data extraction
Three reviewers (VP, AP, LFN-S) collected records in www.myendnoteweb.com. Two independent reviewers (APdR, RC-V) assessed titles and abstracts for eligibility according to the
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inclusion and exclusion criteria. Discrepancies were resolved by discussion. Three reviewers
(LFN-S, APdR, RC-V) assessed full-text articles of selected studies. If two reviewers were
unable to reach consensus, they consulted a third review author (AP). Three independent
reviewers (LFN-S, APdR, RC-V) extracted data with disagreements resolved by a third
reviewer (AP). Extracted information included: study authors, year of publication, study
design, number of patients, country, median age, proportion of males, comorbidities (obesity,
hypertension, diabetes, coronary artery disease (CAD), chronic kidney disease, chronic
obstructive pulmonary disease), PCR method for COVID-19 diagnosis, remdesivir dose and
duration, concomitant treatments for both arms, primary outcomes per arm, and secondary
outcomes per arm.

Outcomes
Primary outcomes were: all-cause mortality, clinical improvement (e.g. 2-point reduction in a
6-point ordinal severity scale), time to recovery (defined as first day, during 28-day enrollment, on which a patient satisfied categories 1, 2, or 3 of an 8-point ordinal scale), need for
invasive ventilation (mechanical [MV], extracorporeal membrane oxygenation [ECMO]), and
serious adverse events (SAE). Secondary outcomes were length of hospital stay, components of
ordinal severity scales, radiological progression of pneumonia, and adverse events (AE).

Assessment of risk of bias
Assessment of risk of bias was performed independently by two investigators (VP, AVH)
using the Cochrane RoB 2.0 tool [10] for RCTs. We planned to independently use the
ROBINS-I tool [11] for cohort studies but no observational studies were found. A third
reviewer (AP) resolved discrepancies when needed.

Statistical analyses
We reported our systematic review according to 2009 PRISMA guidelines [12]. Effects of
remdesivir on outcomes from individual studies were reported as hazard ratio (HR) or risk difference (RD) or relative risk (RR) for dichotomous outcomes and mean differences (MD) for
continuous outcomes, each with 95% confidence intervals (95% CIs). Inverse variance random
effect meta-analyses were performed when outcome data was available for at least two RCTs
judged to have homogeneous study characteristics. Between study variance tau2 was calculated
with the Paule-Mandel method. Effects of meta-analyses were reported as relative risks (RR)
and their 95%CIs, and heterogeneity of effects among studies was quantified with the I2 statistic (an I2>60% means high heterogeneity of effects). R 3.5.1 (www.r-project.org) was used for
meta-analyses. The quality or certainty of evidence was evaluated using the GRADE methodology, which covers 5 items: risk of bias, inconsistency, indirectness, imprecision, and publication bias [13]. Quality of evidence was evaluated per specific comparison and per outcome,
and described in summary of findings (SoF) tables; GRADEpro GDT was used to create SoF
tables [14].

Results
From our searches, 553 records were screened for eligibility and eleven full-text articles were
assessed (Fig 1). One RCT planned in China (NCT04252664) was suspended on April 15th,
2020. Five articles were excluded leaving two placebo-controlled RCTs (n = 1300), two RCTs
comparing 5-day vs. 10-day regimens of remdesivir with or without a standard of care arm
(n = 997), and two case series (n = 88) [15–20].
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Fig 1. Flowchart of study selection.
https://doi.org/10.1371/journal.pone.0243705.g001

Five of the six included studies had patients with similar baseline characteristics including
severe or life-threatening patients with an oxygen saturation <94%. The Spinner et al. trial was
unique in that it evaluated patients with mild to moderate severity of disease. The sample sizes
ranged from 35 to 53 participants across case series, and 236 to 1063 across trials. Most of
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these studies compared intravenous (IV) remdesivir 200 mg as a loading dose and then 100
mg daily for 10 days vs. placebo or standard of care. However, Goldman et al. provided the
200mg loading dose to all participants and compared the 100mg daily dose for10 days vs. 5
days. The follow-up timeframe was 28 days in both case series and ranged between 11 and 29
days across trials.
The description and demographic information of the included studies are shown in
Table 1. The median age of patients was between 63 to 64 years across case series and 58 to 66
years across trials. There was a predominance of male gender ranging between 56.3% to 75.4%
across studies and comorbidities such as hypertension (24.5% to 50%) and diabetes (8.6% to
30.6%) varied between trials. Similar concomitant treatments were given in the trials such as
corticosteroids, antivirals, antibiotics, and support therapy according to each hospital policy.

Description of studies
Wang et al. RCT. The RCT by Wang et al. (NCT04257656) assessed IV remdesivir 200
mg on day one, followed by 100mg IV once-daily for nine more days vs. placebo in adults with
RT-PCR confirmed SARS-CoV-2 infection, pneumonia, and respiratory insufficiency in
Wuhan, China (Table 1) [15]. The primary outcome was the time to clinical improvement
within 28 days after randomization or time discharged alive from the hospital, whichever
came first. Clinical improvement was defined as a decline of two points using a 6-point ordinal
severity scale (Table 1). This scale was modified from a 7-point ordinal severity scale used by
the COVID-19 lopinavir/ritonavir RCT by Cao et al. [21], which has been used in previous
influenza studies by Wang et al. [22] and recommended by the World Health Organization
(WHO) R&D Blueprint expert group [23].
Due to higher occurrence of AEs leading to drug discontinuation vs. placebo (12% vs 5%),
the trial was stopped early, with 236 patients and a statistical power of 56%. Authors mentioned that they followed specific a priori termination criteria, but these are not available in
the protocol [24]. Some imbalances existed at enrollment between arms, including more
patients with hypertension, diabetes, or CAD in the remdesivir arm. Also, more patients in the
control group had been symptomatic for �10 days at the time the intervention was started.
Beigel et al. Adaptive COVID-19 Treatment Trial (ACTT-1). The multinational Beigel
et al. ACTT-1 RCT (NCT04280705) evaluated remdesivir 200 mg IV on day 1, followed by a
100mg IV once-daily for nine more days vs. placebo in adults with RT-PCR confirmed SARS-CoV-2 infection, pneumonia, and respiratory insufficiency (Table 1) [16, 25]. According to
clinicaltrials.gov, on February 20th 2020, its primary outcome was supposed to be percentage
of each severity category at 15 days on the 7-point ordinal scale by Cao et al. [21]. On March
20th 2020, the primary outcome was changed to a new 8-point ordinal severity scale, in which
a subdivision into two groups was made on hospitalized patients (Table 1).
On March 22nd 2020, blinded statisticians recommended again changing the outcome to
time to recovery, defined as the first day during the 28 days satisfying category 1, 2 or 3 of the
8-point scale [16]. This trial was stopped on April 29th 2020, as its safety monitoring board
determined the primary efficacy endpoint had been achieved [25, 26]. At that moment, 1063
had been recruited with 482 recoveries and 81 deaths entered to the database [16]. No substantial imbalances in baseline characteristics were observed between the remdesivir and placebo
arms.
Goldman et al. GS-US-540-5773 RCT. The multinational Goldman et al. GS-US-5405773 Gilead RCT (NCT04292899) evaluated the efficacy and safety of 5-day vs. 10-day remdesivir in patients �12 years-old, PCR confirmed SARS-CoV-2 infection, pneumonia and respiratory insufficiency (Table 1) [19]. The primary outcome was changed after enrollment from
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Table 1. Description of characteristics of included studies.
Grein et al. [17]

Antinori et al. [18]

Wang et al. [15]

Beigel et al. ACTT-1
[16]

Goldman et al. [19]

Spinner et al.
SIMPLE [20]

Design

Case series

Case series

RCT

RCT

RCT

RCT

Country(ies)

United States, Japan,
Italy, Austria, France,
Germany,
Netherlands, Spain,
Canada

Italy

China

Denmark, Germany,
Greece, Japan, Korea,
Mexico, Singapore,
Spain, United
Kingdom, United
States

United States, Italy,
Spain, Germany,
Hong Kong,
Singapore, South
Korea, Taiwan

United States,
China, France,
Germany,
Hong Kong,
Italy, Japan,
Korea, the
Netherlands,
Singapore,
Spain, Sweden,
Switzerland,
Taiwan and
the United
Kingdom

Population

Adults with COVID19 RT-PCR +, O2 sat
<94%, within 15 days
of symptom onset.

Adults with COVID 19
RT-PCT +, O2 sat <94% or
mechanically ventilated or
NEWS2 score �4, within 10
days of symptom onset.

Adults with COVID19 RT-PCR
+ infection,
pneumonia in chest
imaging, sat O2 <
94% or PaO2/FiO2 <
300mmHg, within 12
days of symptom
onset.

Patients � 18 years
old with COVID-19
PCR + infection
(72hrs prior
randomization
or > 72hrs if disease
consistent with
COVID-19),
radiographic
infiltrates in chest
imaging or sat O2 <
94% or requiring
supplemental O2 or
requiring mechanical
ventilation. Within 13
days of symptom
onset.

Patients �12 years
old, PCR + COVID19 confirmed
infection, sat O2
�94% and radiologic
image of pneumonia.
Within 12 days of
symptom onset.

Patients �12
years old with
SARS-CoV2-confirmed
moderate
COVID-19
infection and
evidence of
pneumonia
without
reduced
oxygen levels
(sat O2
>94%).

Exclusion criteria

No exclusion criteria
specified in any
segment of the
manuscript,
supplement or
protocol.

ALT or AST >5 times the
upper limit of the normal
range; creatinine clearance
<30 mL/min

Pregnancy or
breastfeeding; hepatic
cirrhosis; ALT or AST
more than five >5
times the upper
normal of limit;
known severe renal
impairment
(estimated
Glomerular filtration
rate <30mL/min per
1.73 m2 or receipt of
continuous RRT,
hemodialysis, or
peritoneal dialysis:
possibility of transfer
to a non-study
hospital within 72hr;
enrolment into an
investigational
treatment study for
COVID-19 in the 30
days before screening.

ALT or AST > 5 times
the upper limit of
normal; stage 4 severe
CKD or requiring
dialysis (i.e.
eGFR < 30);
pregnancy or
breastfeeding;
anticipated transfer to
another hospital
which is not a study
site within 72 hours;
allergy to any study
medication

ALT or AST > 5 times
the upper limit of
normal, estimated
creatinine clearance of
less than 50 ml per
minute (by the
Cockcroft–Gault
formula), receiving
concurrent treatment
(within 24 hours
before the start of trial
treatment) with other
agents with putative
activity against Covid19.

ALT or AST
>5 times the
upper limit of
the normal
range;
creatinine
clearance
<50mL/min

Sample size

53

35

236

1063

397

600
(Continued )
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Table 1. (Continued)
Grein et al. [17]

Antinori et al. [18]

Wang et al. [15]

Beigel et al. ACTT-1
[16]

Goldman et al. [19]

Spinner et al.
SIMPLE [20]

Reported primary
outcome

Proportion of clinical
improvement (live
discharge from the
hospital, a decrease of
at least two points
from baseline on the
modified 6-point
ordinal severity scale)

Change in patient
hospitalization status using a
7-point ordinal severity scale
(1, not hospitalized, capable
of resuming normal
activities; 2, not hospitalized
but unable to resume normal
activities; 3, hospitalized, not
requiring O2
supplementation; 4,
hospitalized and requiring O2
therapy; 5, hospitalized and
requiring high flow nasal O2
therapy, non-invasive MV, or
both; 6, ICU hospitalization,
requiring invasive MV or
ECMO, or both; 7, death.

Time to clinical
improvement within
28 days or discharged
alive from hospital.
Clinical improvement:
decline of two points
using a 6-point
ordinal severity scale
(6 = death,
5 = hospital admission
for ECMO or MV,
4 = hospital admission
for non-invasive
ventilation or highflow O2 therapy,
3 = hospital admission
for O2 therapy (low
flow O2 therapy),
2 = hospital admission
without O2 therapy,
and 1 = discharged or
having reached
clinical recovery).

Time to recovery at 29
days (Preliminary
report at day 15).
Recovery was defined
as the first day during
the 28 days after
enrollment on which a
patient satisfied
category 1, 2 or 3 in
the 8-point category
scale (1, not
hospitalized, no
limitations of
activities; 2, not
hospitalized,
limitation of activities,
home O2 requirement,
or both; 3,
hospitalized, not
requiring
supplemental O2 and
no longer requiring
ongoing medical care
(used if
hospitalization was
extended for
infection-control
reasons); 4,
hospitalized, not
requiring
supplemental O2 but
requiring ongoing
medical care (Covid19– related or other
medical conditions);
5, hospitalized,
requiring any
supplemental O2; 6,
hospitalized, requiring
noninvasive
ventilation or use of
high-flow oxygen
devices; 7,
hospitalized, receiving
invasive MV or
ECMO; and 8, death).

Clinical status on day
14, assessed on a
7-point ordinal
severity scale (1,
death; 2, hospitalized,
receiving invasive MV
or ECMO; 3,
hospitalized, receiving
non-invasive
ventilation or highflow O2 devices; 4,
hospitalized, requiring
low-flow
supplemental O2; 5,
hospitalized, not
requiring
supplemental O2 but
receiving ongoing
medical care (related
or not related to
Covid-19); 6,
hospitalized, requiring
neither supplemental
O2 nor ongoing
medical care (other
than that specified in
the protocol for
remdesivir
administration); 7, not
hospitalized)

Clinical status
on day 11,
assessed on a
7-point
ordinal
severity scale;
including: �
2-point
improvement
in ordinal
scale,
�1-point
improvement
in ordinal
scale,
Requiring any
oxygen
support, �
1-point
worsening in
ordinal scale,
and death.

Intervention

Remdesivir 200mg loading
Remdesivir 200mg
dose day 1˚, then 100mg
loading dose day 1˚,
then 100mg once daily once daily for a up to 10 days
for a up to 10 days

Remdesivir 200mg
loading dose day 1˚,
then 100mg once daily
for a up to 10 days

Remdesivir 200mg
loading dose day 1˚,
then 100mg once daily
for a up to 10 days

Remdesivir 200mg
loading dose day 1˚,
then 100mg once daily
for a up to 5 days

Remdesivir
200mg loading
dose day 1˚,
then 100mg
once daily for
a up to 10 days
(5-day course
or 10-day
course)

Comparator

None

None

Placebo (blinded)

Placebo (blinded)

Remdesivir 200mg
Standard of
loading dose day 1˚,
care
then 100mg once daily
for a up to 10 days

Follow up time

28 days

28 days

28 days

29 days

14 days

11 days
(Continued )
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Table 1. (Continued)
Grein et al. [17]
Concomitant
treatment

Age (median,
IQR)
Male (%)

Support therapy

Antinori et al. [18]
Hydroxychloroquine

Wang et al. [15]
Support therapy,
steroids, lopinavir/
ritonavir, interferon
alfa 2b

Beigel et al. ACTT-1
[16]
Support therapy and
other treatments
indicated in written
hospital policy

Goldman et al. [19]
Support therapy

Intervention

Intervention

64 (48–71)

63 (51–69)

66 (57–73)

64 (53–
70)

58.6 (14.6)

59.2
(15.4)

61 (50–69)

40 (75.4)

26 (74.3)

89 (56.3)

51
(65.3)

352 (65.1)

332
(63.6)

13 (24.5)

12 (34.3)

72 (45.6)

30
(38.4)

231 (49.3)

9 (17)

2 (8.6)

40 (25.3)

16
(20.5)

144 (30.6)

6 (11.3)

NA

15 (9.5)

2 (2.5)

NA

NA

NA

NA

NA

61 (13)

6 (11.3)

NA

NA

NA

59 (12.6)

47
(10.3)

Spinner et al.
SIMPLE [20]
Standard of
care

Intervention Control Intervention Control Intervention Control

5-day
course

SOC

62 (50–
71)

58
(46–
66)

57
(45–
66)

120 (60)

33
(67.5)

114
(60.0)

125
(62.5)

229
(49.9)

100 (50)

98
(49.2)

82
(42.9)

81
(40.5)

131
(28.7)

47 (23.5)

43
(21.8)

71
(37.0)

76
(38.0)

NA

NA

NA

NA

NA

46 (8.8)

40 (20)

49
(24.9)

111
(58.1)

107
(53.5)

27 (13.5)

22
(11.2)

22
(11.5)

28
(14.0)

Comorbidities (n,
%)
-Hypertension
-DM
-Hyperlipidemia
-CHD
-Asthma
6-point ordinal
severity scale at
baseline (n, %)
�

†

§

§

k

k

¶

¶

¶

¶

-Category 1

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

-Category 2

2 (3.8)

1 (2.9)

0 (0)

3 (3.8)

67 (12.4)

60
(11.5)

34 (17)

21
(10.7)

160
(83.8)

162
(81.0)

-Category 3

10 (18.9)

2 (5.7)

129 (81.6)

65
(83.3)

222 (41)

199
(38.1)

113 (56.5)

113
(54.3)

29
(15.2)

36
(18.0)

-Category 4

7 (13.2)

16 (45.7)

28 (17.7)

9 (11.5)

98 (18.1)

99 (19)

49 (24.5)

60
(30.5)

2 (1.0)

2
(1.0)

-Category 5

34 (64.1)

16 (45.7)

0 (0)

1 (1.3)

125 (23.1)

147
(28.2)

4 (2.0)

9 (4.6)

0 (0)

0 (0)

-Category 6

0 (0)

0 (0)

1 (0.7)

0

0 (0)

0 (0)

0 (0)

0 (0)

6-point ordinal
severity scale after
treatment (n, %)
�

†

§

§

k

k

-Category 1

25 (47.2)

20 (57.1)

39 (25.4)

18 (23)

257 (59.2)

203
(49.5)

-Category 2

8 (15.1)

1(2.9)

21 (13.7)

10
(12.8)

34 (7.8)

26 (6.4)

-Category 3

0 (0)

1(2.9)

61 (39.9)

28
(35.9)

34 (7.8)

-Category 4

3 (5.7)

1(2.9)

13 (8.6)

8 (10.3)

-Category 5

10 (18.9)

3 (8.5)

4 (2.6)

-Category 6

7 (13.2)

9 (25.7)

15 (9.8)

¶

¶

¶

¶

103
(53.3)

134
(70.2)

120
(60.0)

20 (10.0)

16 (8.1)

45
(23.6)

54
(27.0)

40 (9.8)

19 (9.5)

14 (7.1) 7 (3.7)

11
(5.5)

16 (3.7)

14 (3.4)

9 (4.5)

10 (5.1) 5 (2.6)

7
(3.5)

7 (9.0)

60 (13.8)

72
(17.6)

16 (8.0)

33
(16.7)

7 (9.0)

33 (7.6)

55
(13.4)

16 (8).0

21
(10.7)

120 (60.0)

0 (0)

4
(2.0)

(Continued )
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Table 1. (Continued)

Clinical
improvement/
recovery at day 28
(n, %)

Grein et al. [17]

Antinori et al. [18]

36 (67.9)

22 (62.8) ‡

Wang et al. [15]

103 (65.0)

Beigel et al. ACTT-1
[16]

45 (58)

NA

NA

Goldman et al. [19]

Spinner et al.
SIMPLE [20]

#

#

��

��

129 (64.5)

107
(54.3)

134
(70.2)

121
(60.5)

IQR: Interquartile range; CAD: Coronary artery disease; NA: Not applicable; O2: Oxygen; ICU: Intensive care unit; MV: Mechanical ventilation; ECMO: Extracorporeal
membrane oxygenation; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CKD: chronic kidney disease; RRT: renal replacement therapy.
After treatment: day 15.

�

†

7-category ordinal scale in this study have been adapted to this table. We combined category 1 and 2 to fit the 6-point ordinal severity scale. After treatment: day 28.

‡

The study main outcome was to assess any change in hospitalization status according to the 7-point ordinal severity scale. For the purposes of this table, we have
considered the patients that had a positive change in clinical status at day 28th. In this scenario, 15 patients out the Infectious diseases wards and 7 patients in the
intensive care unit had clinically changed to a better clinical status.

§
k

After treatment: day 14.
8-category ordinal scale in this study has been adapted to this table. We combined category 1 and 2; and 3 and 4 to fit the 6-point ordinal severity scale. After treatment:

day 15.
¶

7-category ordinal scale in this study has been adapted to this table. We reversed the categories since the scale was inverted as compared with the other studies. We
combined their category 6 and 5 as hospitalized but not requiring supplemental oxygen. The rest of the categories are the same but inverted. After treatment day 14.

#

At day 14.

��

Clinical improvement defined as improvement in 2 or more points in ordinal severity scale, at day 11.

https://doi.org/10.1371/journal.pone.0243705.t001

proportion of patients with normalization of temperature at day 14 to clinical status evaluated
at 14 days by a 7-point ordinal severity scale based on the 6-point scale of Wang et al. [15] but
divided their non-oxygen user hospitalized patients into two categories regarding their need
for clinical care. Both groups received supportive therapy at the discretion of the clinician. Secondary outcomes were time to clinical improvement (�2 points of ordinal scale), time to
recovery (improvement from a baseline score of 2–5 to 6–7), time to modified recovery
(improvement from a baseline score of 2–4 to 5–7 or from 5 to 6–7), all-cause mortality and
safety.
Spinner et al. SIMPLE RCT. Gilead’s open-label SIMPLE trial (NCT04292730) evaluated
the efficacy and safety of remdesivir 5-day or 10-day plus standard of care vs. standard of care
alone in hospitalized patients with SARS-CoV-2 confirmed infection and moderate pneumonia (e.g. without reduced oxygen levels) [20]. The primary outcome was clinical status evaluated by a 7-point ordinal severity scale at day 11 and the secondary outcome was the rate of
adverse events between treatment arms. Clinical improvement was defined as 2 points
improvement in the 7-point ordinal scale; also, a one-point improvement was assessed as well
as the requirement of oxygen support or worsening of one point in the scale.
Case series. The case series by Grein et al. [17] assessed 53 RT-PCR confirmed COVID19 patients, with oxygen saturation <94% receiving a similar 10-day remdesivir regimen and
follow up as placebo-controlled RCTs [15, 16]. Clinical improvement (live discharge from the
hospital, a decrease of �2 points on a modified 6-point ordinal scale) as suggested by the
WHO [23], changes in oxygen support, AEs, discharge, and deaths were recorded. Mean age
was 64 years and 75% were male. About 60% had hypertension, diabetes, hyperlipidemia and
asthma and most were on low flow oxygen support or invasive ventilation.
The case series by Antinori et al. evaluated 35 RT-PCR confirmed COVID-19 patients, with
oxygen saturation <94% or mechanically ventilated or NEWS-2 score �4 [18] with similar
remdesivir regimen and follow up as RCTs. They used the 7-point ordinal scale used by Cao
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Fig 2. Effect of remdesivir on all-cause mortality at 14 days.
https://doi.org/10.1371/journal.pone.0243705.g002

et al. [21] Median age was 63 years, 74% male, with 9% diabetes and 34% hypertension. Eighteen patients were in the ICU and 17 in an infectious disease ward.

Effect of remdesivir on primary outcomes
There was no significant reduction in all-cause mortality vs. placebo at 14 days (RR 0.71, 95%
CI 0.39 to 1.28, I2 = 43%, Fig 2). There was no difference in mortality between 5-day and
10-day remdesivir arms in Goldman et al. (RR 0.75, 95%CI 0.40 to 1.40) [19]. All-cause mortality was not different between the 10-day, 5-day and SOC arms at 11 days (1%, 0%, 2%, respectively), and at 28 days (2%, 1%, 2%, respectively) in the Spinner et al. trial. [20] Grein et al.
reported that 13% died [17], whereas in Antinori et al. 26% died [18].
Time to clinical improvement was not different between arms in Wang et al. (HR 1.23, 95%
CI 0.87–1.75), but time to recovery was significantly shorter with remdesivir in Beigel et al. (11
days, 95%CI 9 to 12 vs. 15 days, 95% CI 13 to 19, RR for recovery 1.32; 95%CI 1.12 to 1.55) in
comparison with placebo. In Goldman et al., time to recovery (HR 0.81, 95%CI 0.64 to 1.04)
and time to clinical improvement (HR 0.79, 95%CI 0.61 to 1.01) were different between arms
[19]. In the Spinner et al. trial, the odds of clinical improvement at day 11 was higher for 5-day
(134/191 [70.2%], RD 9.7%, 95%CI 0.1% to 19.1%) but not for 10-day (126/193 [65.3%], RD
4.8%, 95%CI -5.0% to 14.4%) remdesivir vs. standard of care (121/200 [60.5%]) [20].
Remdesivir did not decrease the need for invasive ventilation vs. placebo at 14 days (RR
0.57, 95%CI 0.23 to 1.42, I2 = 60%, Fig 3). Five-days of remdesivir treatment reduced the need
for invasive ventilation vs. 10-day in Goldman et al. (RR 0.48, 0.27 to 0.84) [19]. SAEs were significantly lower with remdesivir vs. placebo (RR 0.77, 95%CI 0.63 to 0.94) (S1 Fig). In Beigel
et al. ACCT-1, SAEs were present in 21% vs. 27% in remdesivir and placebo, respectively [16].
The most common SAEs were acute respiratory failure, hypotension, viral pneumonia and
acute kidney injury but were more frequent in the placebo arm. In Goldman et al., SAEs were
more frequent in the 10-day remdesidivir arm (21% vs 35%), with respiratory failure being the
most commonly seen [19]. SAEs were less frequent in the 5-day and 10-day remdesivir vs.
SOC arms (4.7%, 5.2%, and 9.0%) in the Spinner et al. trial [20]. Grein et al. reported 23% of
SAEs, most commonly multiple organ failure, septic shock, kidney injury and hypotension
with an 8% drug discontinuation rate [17].

Fig 3. Effect of remdesivir on invasive ventilation at 14 days.
https://doi.org/10.1371/journal.pone.0243705.g003

PLOS ONE | https://doi.org/10.1371/journal.pone.0243705 December 10, 2020

10 / 19

PLOS ONE

Efficacy and harms of remdesivir for the treatment of COVID-19

Effect of remdesivir on secondary outcomes
There was no effect of remdesivir on hospitalization without oxygen or with oxygen support/
non-invasive ventilation vs. placebo (S2 and S3 Figs; explanation of ordinal scale re-categorization across RCTs in S3 File). A higher proportion of patients were discharged if treated with
remdesivir (S4 Fig), and there was no difference in treatment discontinuation (S5 Fig) vs. placebo. There was no difference in AEs in the two placebo-controlled RCTs (RR 0.94, 95%CI
0.81 to 1.10) (S6 Fig). AEs were similar between 5-day and 10-day remdesivir arms (71 vs 74%)
[17], but higher in 5-day or 10-day arm vs. standard of care arm (51.3%, 58.5%, 46.5%) [18].
No differences were found between remdesivir vs. placebo on specific AEs such as anemia, elevated liver enzymes, hyperbilirubinemia, hypoalbuminemia, deep vein thrombosis, pulmonary
embolism or renal impairment (S7–S13 Figs).
Antinori et al. reported that 43% of subjects had elevated liver enzymes, 23% had acute kidney injury, and 20% had elevated bilirubin levels [18]. Overall, 23% of AEs led to drug discontinuation [18]. Grein et al. reported that 60% of patients experienced AEs including elevated
liver enzymes (23%), diarrhea (9%) and rash (8%) [17]. None of the studies documented radiological progression of pulmonary disease or viral clearance.

Quality of evidence and risk of bias of RCTs
The quality of evidence for primary and secondary outcomes per comparison are shown in
Table 2 (remdesivir 10 days vs. placebo), Table 3 (remdesivir 5 days vs. 10 days), Table 4
(remdesivir 5 days vs. standard of care), and S1 Table (remdesivir 10 days vs. standard of care).
Overall quality of evidence was low or very low for all primary and secondary outcomes,
mainly due to some concerns or high risk of bias among RCTs, and inconsistency and imprecision of effects. Indirectness was present when assessing the Spinner et al. trial as its population
were moderate COVID-19 patients in contrast to severe COVID-19 patients in other three trials. The risk of bias analysis of four RCTs using Cochrane’s RoB 2.0. tool is shown in S14 and
S15 Figs. The Wang et al. trial was judged to have some concerns due to potential confounding
on the randomization process. The Beigel et al. trial was judged to have high risk of bias due to
selection of the reported results, as their primary outcome was time to recovery after two previous changes. The Goldman et al. trial was judged to have serious risk of bias due to the measurement of the outcome, as they used a non-validated 7-point disease severity scale. The
Spinner et al. trial was judged to have some concerns due to selection of the reported results.

Ongoing trials
S2 Table describes details of four ongoing remdesivir RCTs [27–33]. Further details of these
RCTs can also be found in the S2 File.

Discussion
In adult, hospitalized, RT-PCR confirmed COVID-19 patients with respiratory insufficiency
or pneumonia, there were scarce data on efficacy and safety associated with the use of 10-day
remdesivir regimens, or with the comparison of 5-day or 10-day regimens vs. standard of care.
Two RCTs used a common treatment regimen and a true placebo control, and two RCTs compared two different doses of remdesivir, including one RCT with standard of care. Three trials
were focused on severely ill COVID-19 patients, while one RCT was in mild to moderate
COVID-19 patients. Remdesivir did not decrease all-cause mortality and need for invasive
ventilation vs. placebo at 14 days but had fewer SAEs. Five-days of remdesivir decreased need
for invasive ventilation and SAEs vs. 10-days of therapy. No differences in all-cause mortality
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Table 2. Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19.
Patient or population: hospitalized, severe COVID-19
Setting: Hospital
Intervention: remdesivir for 10 days
Comparison: placebo
Anticipated absolute effects� (95%
CI)

Outcomes

Relative effect
(95% CI)

No of participants
(studies)

Certainty of the
evidence (GRADE)

Risk with
placebo

Risk with remdesivir
for 10 days

All-cause mortality follow up: range 15 days to 28 days

10 per 100

7 per 100 (4 to 13)

RR 0.71 (0.39 to
1.28)

1290 (2 RCTs)

⊕◯◯◯ VERY
LOW a,b,c

Clinical improvement assessed with: Decline of 2 points using
6-points ordinal severity scale follow up: 28 days

58 per 100

65 per 100 (53 to 78)

HR 1.23 (0.87 to
1.75)

236 (1 RCT)

⊕⊕◯◯ LOW d,e

Recovery assessed with: First day when patient satisfied
categories 1, 2 or 3 of an 8-point ordinal severity scale follow
up: 15 days

52 per 100

69 per 100 (59 to 81)

Rate ratio 1.32
(1.12 to 1.55)

1059 (1 RCT)

⊕⊕◯◯ LOW f

Need for invasive ventilation follow up: 14 days

16 per 100

9 per 100 (4 to 23)

RR 0.57 (0.23 to
1.42)

1075 (2 RCTs)

⊕◯◯◯ VERY
LOW a,g,h

Hospitalization without oxygen follow up: 15 days

7 per 100

9 per 100 (6 to 13)

RR 1.18 (0.79 to
1.76)

1075 (2 RCTs)

⊕◯◯◯ VERY
LOW a,i

Hospitalization with oxygen support or non-invasive
ventilation follow up: 15 days

18 per 100

18 per 100 (14 to 23)

RR 0.98 (0.78 to
1.22)

1075 (2 RCTs)

⊕⊕◯◯ LOW a

Discharge follow up: 15 days

45 per 100

54 per 100 (48 to 61)

RR 1.19 (1.05 to
1.34)

1075 (2 RCTs)

⊕⊕◯◯ LOW a

Serious adverse events follow up: range 15 days to 28 days

27 per 100

21 per 100 (17 to 25)

RR 0.77 (0.63 to
0.94)

1296 (2 RCTs)

⊕⊕◯◯ LOW a

Adverse events follow up: range 15 days to 28 days

37 per 100

35 per 100 (30 to 41)

RR 0.94 (0.81 to
1.10)

1296 (2 RCTs)

⊕⊕◯◯ LOW a

Explanations
a

. RoB: Wang et al. had some concerns of bias in the randomization process, and Beigel et al. had high risk of bias in the selection of the reported result.
. Inconsistency: I2 = 43%.

b
c

. Imprecision: 95%CI of effect is 0.39 to 1.28.

d

. RoB: Wang et al. had some concerns of bias in the randomization process.
. Imprecision: 95%CI of effect is 0.87 to 1.75.

e
f

. RoB: Beigel et al. had high risk if bias in the selection of reported result.

g

. Inconsistency: I2 = 60%.
. Imprecision: 95%CI is 0.23 to 1.42.

h
i

. Imprecision: 95%CI is 0.79 to 1.76.

https://doi.org/10.1371/journal.pone.0243705.t002

or SAEs were seen among 5-days of 10-days of remdesivir and standard of care. Time to recovery was decreased by 4 days when remdesivir was compared to placebo, and by 0.8 days when
patients were given 5-days of remdesivir vs. 10-days of therapy. Clinical improvement was
higher with5-days of remdesivir vs. standard of care. The RCTs ranged from some concerns of
bias to high risk of bias, and quality of evidence was low to very low for all outcomes and all
comparisons.
The RCTs used different primary outcomes. The Wang et al. trial evaluated time to clinical
improvement at 28 days, Beigel et al. trial evaluated time to recovery at 29 days and reported at
15 days, Goldman et al. evaluated clinical status at day 14, and Spinner et al. evaluated clinical
status at day 11. Each of them used similar ordinal scale of disease severity. Furthermore, the
four RCTs assessed the safety of this drug by measuring overall, specific and serious adverse
events. The two-case series provided additional information about these outcomes as well.
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Table 3. Summary of findings table for the comparison of remdesivir 5 days vs. remdesivir 10 days for hospitalized, severe COVID-19.
Patient or population: hospitalized, severe COVID-19
Setting: Hospital
Intervention: remdesivir for 5 days
Comparison: remdesivir for 10 days
Anticipated absolute effects� (95% CI)

Outcomes

Relative effect
(95% CI)

No of participants
(studies)

Certainty of the
evidence (GRADE)

Risk with remdesivir
for 10 days

Risk with
remdesivir for 5
days

All-cause mortality follow up: 14 days

11 per 100

8 per 100 (4 to 15)

RR 0.75 (0.40
to 1.40)

397 (1 RCT)

⊕◯◯◯ VERY
LOW a,b

Clinical improvement assessed with: Improvement of at
least 2 points in a 7-point ordinal scale follow up: 14 days

54 per 100

46 per 100 (38 to
55)

HR 0.79 (0.61
to 1.01)

397 (1 RCT)

⊕⊕◯◯ LOW a

Recovery assessed with: Improvement from a baseline
score of 2–5 to 6–7 in a 7-point ordinal scale follow up: 14
days

54 per 100

47 per 100 (39 to
55)

HR 0.81 (0.64
to 1.04)

397 (1 RCT)

⊕⊕◯◯ LOW a

Need for invasive ventilation follow up: 14 days

17 per 100

8 per 100 (5 to 14)

RR 0.48 (0.27
to 0.84)

397 (1 RCT)

⊕⊕◯◯ LOW a

Hospitalization without oxygen follow up: 14 days

8 per 100

10 per 100 (5 to 19)

RR 1.23 (0.66
to 2.31)

397 (1 RCT)

⊕◯◯◯ VERY
LOW a,c

Hospitalization with oxygen support or non-invasive
ventilation follow up: 14 days

12 per 100

14 per 100 (8 to 23)

RR 1.15 (0.69
to 1.91)

397 (1 RCT)

⊕◯◯◯ VERY
LOW a,d

Discharge follow up: 14 days

52 per 100

60 per 100 (50 to
72)

RR 1.15 (0.96
to 1.37)

397 (1 RCT)

⊕⊕◯◯ LOW a

Serious adverse events follow up: 14 days

35 per 100

21 per 100 (15 to
29)

RR 0.61 (0.44
to 0.85)

397 (1 RCT)

⊕⊕◯◯ LOW a

Adverse events follow up: 14 days

74 per 100

71 per 100 (63 to
79)

RR 0.96 (0.85
to 1.08)

397 (1 RCT)

⊕⊕◯◯ LOW a

Explanations
a

. RoB: Goldman et al. is at high risk of bias due to bias of measurement of the outcome.

b

. Imprecision: 95%CI of effect is 0.40 to 1.40.
. Imprecision: 95%CI of effect is 0.66 to 2.31.

c

d

. Imprecision: 95%CI of effect is 0.69 to 1.91.

https://doi.org/10.1371/journal.pone.0243705.t003

While overall mortality is the most important final health outcome, it was not the primary
endpoint of any of the available trials. Clinical severity is a relevant clinical outcome, but the
ordinal scale used in these trials has not been validated before or appropriately analyzed.
Indeed, there is not a correlation between clinical important differences and changes in scale
scores in these trials. That may be because only the Beigel et al. and Spinner et al. trials used
the proportional odds models and no trial used other methods such as the sliding dichotomy
model. Serious adverse events, such as acute respiratory failure, acute kidney injury, and hypotension, are relevant as main metrics of safety.
Wang et al. RCT was stopped prematurely due to an excess of serious adverse events causing drug discontinuation, and Beigel et al. preliminarily reported their data at 15-days. While
Wang et al. stated the use of a priori protocol that specified their stopping rule, there is no
independent verification in their publicly available protocol. The demographic differences,
with more remdesivir patients having hypertension, diabetes, or CAD, would be more likely to
work against remdesivir efficacy. While more patients in the control group had been symptomatic for �10 days at the time of starting the intervention, this is not expected to cause more
outcomes to occur. In Beigel et al., they changed their primary outcome twice [25] with no
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Table 4. Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19.
Patient or population: hospitalized, moderate COVID-19
Setting: Hospital
Intervention: remdesivir for 5 days
Comparison: standard of care
Anticipated absolute effects� (95%
CI)

Outcomes

Relative effect No of participants
Certainty of the
(95% CI)
(studies)
evidence (GRADE)

Risk with
standard of
care

Risk with
remdesivir for 5
days

All-cause mortality follow up: 11 days

2 per 100

0 per 100 (0 to 0)

not estimable

391 (1 RCT)

⊕◯◯◯ VERY
LOW a,b,c

All-cause mortality follow up: 28 days

2 per 100

1 per 100 (0 to 6)

RR 0.52 (0.10
to 2.83)

391 (1 RCT)

⊕◯◯◯ VERY
LOW a,b,d

Clinical status assessed with: 7-point ordinal scale and proportional
odds model follow up: 11 days

0 per 100

0 per 100 (0 to 0)

OR 1.65 (1.09
to 2.48)

391 (1 RCT)

⊕◯◯◯ VERY
LOW a,b,e

Clinical improvement assessed with: Improvement of at least 2
points from baseline on the 7-point ordinal scale follow up: 11 days

61 per 100

70 per 100 (61 to
81)

RR 1.16 (1.00
to 1.34)

391 (1 RCT)

⊕⊕◯◯ LOW a,b

Recovery assessed with: Improvement from a baseline score 2–5 to
a score 6–7 OR from baseline score 6 to score 7 in a 7-point ordinal
scale follow up: 11 days

64 per 100

74 per 100 (65 to
84)

RR 1.15 (1.01
to 1.32)

391 (1 RCT)

⊕⊕◯◯ LOW a,b

Need of invasive ventilation follow up: 11 days

2 per 100

0 per 100 (0 to 0)

not estimable

391 (1 RCT)

⊕◯◯◯ VERY
LOW a,b,c

Hospitalization without oxygen follow up: 11 days

27 per 100

23 per 100 (17 to
33)

RR 0.87 (0.62
to 1.23)

391 (1 RCT)

⊕⊕◯◯ LOW a,b

Hospitalization with oxygen support or non-invasive ventilation
follow up: 11 days

9 per 100

6 per 100 (3 to 13)

RR 0.70 (0.35
to 1.41)

391 (1 RCT)

⊕◯◯◯ VERY
LOW a,b,f

Discharge follow up: 11 days

60 per 100

70 per 100 (61 to
81)

RR 1.17 (1.01
to 1.35)

391 (1 RCT)

⊕⊕◯◯ LOW a,b

Serious adverse events follow up: 11 days

9 per 100

5 per 100 (2 to 10)

RR 0.52 (0.24
to 1.14)

391 (1 RCT)

⊕◯◯◯ VERY
LOW a,b,g

Adverse events follow up: 11 days

47 per 100

51 per 100 (42 to
63)

RR 1.10 (0.90
to 1.35)

391 (1 RCT)

⊕⊕◯◯ LOW a,b

Explanations
a
. RoB: Spinner et al. had some concerns of risk of bias due to bias of selection of the reported result.
b

. Indirectness: Patients were hospitalized with SatO2>94% (no need of oxygen), described as moderate COVID-19.

c

. Imprecision: RR is 0, and the upper 95%CI is infinite.
d
. Imprecision: 95%CI of effect is 0.10 to 2.83.
e

. Imprecision: 95%CI of effect is 1.09 to 2.48.

f

. Imprecision: 95%CI of effect is 0.35 to 1.41.
g
. Imprecision: 95%CI of effect is 0.24 to 1.14.
https://doi.org/10.1371/journal.pone.0243705.t004

clear rationale for this alteration. Goldman et al. RCT also changed their primary outcome
after the beginning of enrollment, and Spinner et al. trial reported their primary outcome at 11
days. In comparison to placebo, remdesivir did not significantly impact all-cause mortality,
need of invasive ventilation, hospitalization without oxygen, hospitalization with oxygen or
non-invasive ventilation, or treatment discontinuation. There was a significantly lower incidence of SAEs and higher proportion of discharged patients in RCTs comparing remdesivir to
placebo. In comparison to 10-days of remdesivir therapy in Goldman et al., the 5-day regimen
did not decrease mortality but decreased need for invasive ventilation and SAEs. AEs were
similar between remdesivir and placebo arms and between the 5-day vs 10-day remdesivir
arms. No differences in all-cause mortality, SAEs or AEs were seen among the 5-day, 10-day
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and standard of care arms in the Skinner et al. trial. There were substantial differences between
the two-case series in the magnitude of their outcomes.
There were some differences in the scales used to assess outcomes across studies as shown
in Table 1. Wang et al. and Grein et al. used the same 6-point ordinal scale, [15, 17] Beigel et al.
used an 8-point scale, and Antinori et al used a 7-point scale. [16, 18]. Goldman et al. used a
7-point scale based on the 6-point scale of Wang et al. [19, 15] and Spinner et al. trial used a
7-point ordinal severity scale without further description [20]. These scales were strongly correlated, and that allowed us to formally group those scale categories in five in order to perform
our meta-analyses for the two placebo-controlled RCTs [15, 16]; explanations are shown in S3
File. It is important to highlight that although these types of scales are based on a blueprint
from WHO, neither of them has been fully validated as a disease severity index, and there is no
current information about a more proper tool to assess the severity of COVID-19 [23].
Remdesivir is FDA approved and indicated for the treatment of hospitalized COVID-19
patients who are 12 years of age and older, and who weigh at least 40 kg. It should only be
administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. We disagree that the currently available data is sufficiently strong
to support its FDA approval, given that it is not possible to fully assess the balance of benefits
to harms in COVID-19 infected patients. There is a risk that the benefits and harms of remdesivir will remain unknown if other remdesivir RCTs vs. placebo are stopped and substituted
with trials where remdesivir becomes the standard of care and other experimental drugs are
added onto remdesivir versus remdesivir alone. Patients may specifically ask for remdesivir
therapy if they are not candidates for corticosteroid therapy and feel a failure to use an FDA
approved option is a substandard practice.
Our systematic review has several strengths. We ran a recent and extensive systematic
search in several engines and websites, and we did not restrict by language. We found commonalities across all studies: adult, hospitalized patients with COVID-19, and in particular
patients with pneumonia and respiratory insufficiency. All six studies evaluated the same loading dose and a similar daily dose, albeit for different days of therapy, and two RCTs were compared to placebo. We also systematically searched for worldwide ongoing RCTs and ongoing
systematic reviews in PROSPERO that can be found in S3 Table.
Some limitations can be highlighted. First, the number of RCTs was scarce, the reporting of
the Beigel et al. trial is based on 15-day outcomes of the totality of recruited patients, and the
Spinner et al. trial compared outcomes over11 days. Second, the Wang et al. RCT was stopped
early because a higher proportion of adverse events leading to drug discontinuation was found
in an unplanned interim analysis [15]. Third, our meta-analyses for primary outcomes and secondary outcomes were based only on two placebo-controlled RCTs and we used outcomes at
similar time points of follow up and re-categorized heterogeneous ordinal outcome scales into
five categories. Based on this, conclusions about mortality, need for invasive ventilation, and
SAEs should be interpreted with caution. Whether it is the six- or seven-point scales used by
investigators, these scales do not have an established minimum clinically important difference.
Finally, three of the RCTs included patients given therapy within 10 to 15 days of when symptoms began. Remdesivir’s antiviral activity should be the highest during the first few days of
active viral multiplication, as supported by a study performed in monkeys where early administration of remdesivir prevent progression to pneumonia after SARS-CoV-2 inoculation [8].

Conclusions
There is paucity of adequately powered and fully reported RCTs evaluating efficacy and harms
of remdesivir use in adult, hospitalized, COVID-19 patients. One RCT was stopped early
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without a clear description of the reasons, the largest trial (Beigel et al. ACTT-1), altered their
primary endpoint twice and only reported 15-day outcomes, the Goldman et al. and Spinner
et al. SIMPLE trials did not have a placebo arm, and the Spinner et al. SIMPLE trial outcomes
were reported at 11 days. Conclusions about overall mortality, need for invasive ventilation,
and SAEs from meta-analyses of two trials should be interpreted with caution. Several ongoing
RCTs should be completed despite the FDA approval in order to determine remdesivir’s clinical efficacy and harm profile. Until stronger evidence emerges, we cannot conclude that
remdesivir is efficacious for treating COVID-19.
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